Literature DB >> 10355701

Effects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia.

Y J Chen1, S H Lee, M H Hsieh, C J Hsiao, W C Yu, C W Chiou, S A Chen.   

Abstract

INTRODUCTION: Gender difference is known to be associated with the occurrence of arrhythmia. However, the effects of female sex hormone on atrial electrophysiology, and on the occurrence of torsades de pointes (TdP) induced by cisapride have been unclear. METHODS AND
RESULTS: Two experiments were included in this study. In experiment 1, effective refractory periods (ERPs) from five epicardial atrial sites were measured before and after rapid atrial pacing at 800 beats/min for 30 minutes in dogs with pretreatment of verapamil (n = 10), 17beta-estradiol (n = 10), or without pretreatment (n = 10, control group). In experiment 2, limb-lead ECG and monophasic action potentials in the left and right ventricles were recorded before and after each dose of cisapride (2 to 6 mg/kg) during different ventricular rates in dogs with (n = 9) and without (n = 14) concomitant administration of 17beta-estradiol (0.3 microg/kg). After 17beta-estradiol administration, there were greater atrial ERPs in the study dogs than in the control group. The atrial ERPs were shortened significantly after rapid atrial pacing, but the degree was greater in the control group than in the dogs pretreated with verapamil or 17beta-estradiol. Moreover, the recovery of atrial ERPs was faster in dogs pretreated with verapamil or 17beta-estradiol than in the control group. In experiment 2, cisapride prolonged the QT interval and biventricular APD90 and induced early afterdepolarizations (EADs) in a dose-dependent manner. However, dogs receiving cisapride combined with 17beta-estradiol had a greater increase of ventricular repolarization and a higher incidence of EADs than those receiving cisapride only. Moreover, dogs receiving cisapride combined with 17beta-estradiol (3/9, 33%) had a greater incidence of TdP than those receiving cisapride only (0/14, 0%, P < 0.05).
CONCLUSIONS: 17beta-estradiol has a significant effect on atrial electrophysiology, which may be related to the prevention of atrial fibrillation. However, the high incidence of TdP in dogs receiving cisapride combined with 17beta-estradiol suggests that the female sex hormone is an important risk factor of cisapride-induced proarrhythmia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10355701     DOI: 10.1111/j.1540-8167.1999.tb00716.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

Review 1.  Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.

Authors:  M D Drici; N Clément
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Behavioral influences on cardiac arrhythmias.

Authors:  Rachel Lampert
Journal:  Trends Cardiovasc Med       Date:  2015-04-17       Impact factor: 6.677

3.  Gender Difference in Idiopathic Right Ventricular Outflow Tract-Ventricular Tachycardia.

Authors:  Jo-Nan Liao; Yu-Feng Hu; Wei-Shiang Lin; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Ta-Chuan Duan; Fa-Po Chung; Cheng-Hung Li; Tze-Fan Chao; Beny Hartono; Shih-Ann Chen
Journal:  Acta Cardiol Sin       Date:  2013-07       Impact factor: 2.672

4.  Feminizing adrenal carcinoma presenting with heart failure and ventricular tachycardia.

Authors:  Anjana Harnoor; R Lee West; Fiona J Cook
Journal:  Case Rep Endocrinol       Date:  2012-06-26

5.  Put on a Happy Face-It's a Lot Better Than Coumadin.

Authors:  Rachel Lampert
Journal:  J Am Heart Assoc       Date:  2012-06-22       Impact factor: 5.501

6.  Long-term results of single-procedure catheter ablation for atrial fibrillationin pre- and post-menopausal women.

Authors:  Tao Lin; Xing Du; Rong Bai; Ying-Wei Chen; Rong-Hui Yu; De-Yong Long; Ri-Bo Tang; Cai-Hua Sang; Song-Nan Li; Chang-Sheng Ma; Jian-Zeng Dong
Journal:  J Geriatr Cardiol       Date:  2014-06       Impact factor: 3.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.